Free Trial
→ Elon says the ‘S’ word (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$283.07
-0.1%		$261.95
$190.75
▼
$291.40
$500.85B0.244.77 million shs7.62 million shs
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$92.38
+5.0%		$107.44
$69.81
▼
$148.83
$7.70B1.141.37 million shs1.52 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.18%+3.99%+7.66%+11.21%+25.08%
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+5.00%+3.74%-13.39%-32.40%-3.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$283.07
-0.1%		$261.95
$190.75
▼
$291.40
$500.85B0.244.77 million shs7.62 million shs
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$92.38
+5.0%		$107.44
$69.81
▼
$148.83
$7.70B1.141.37 million shs1.52 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.18%+3.99%+7.66%+11.21%+25.08%
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+5.00%+3.74%-13.39%-32.40%-3.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$277.18-2.08% Downside
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.88
Moderate Buy$156.6969.62% Upside

Current Analyst Ratings Breakdown

Latest ABVX and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$280.00
10/9/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$288.00
10/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy (B-) ➝ Buy (B)
10/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$285.00 ➝ $300.00
10/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$285.00 ➝ $290.00
10/7/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$296.00 ➝ $310.00
10/6/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$280.00 ➝ $320.00
10/6/2026
AbbVie Inc. stock logo
ABBV
AbbVie
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$260.00 ➝ $275.00
10/6/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Outperform$280.00 ➝ $320.00
9/22/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$155.00 ➝ $151.00
9/22/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetNeutral$140.00 ➝ $118.00
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B8.18$15.12 per share18.72($1.83) per share-154.68
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5479.9617.641.299.80%-422.07%14.34%10/30/2026 (Estimated)
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$6.06N/AN/AN/AN/A-91.69%-71.96%12/21/2026 (Estimated)

Latest ABVX and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.74N/AN/AN/A$17.36 billionN/A
9/21/2026Q2 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9170-$1.71-$0.7930-$1.68$0.80 million$1.37 million
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.44%+6.80%195.48%53 Years
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A

Latest ABVX and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
5.97
5.97

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
8087.53 millionN/ANot Optionable

Recent News About These Companies

Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Has Average Price Target of $156.69
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31124017
Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-abivax-sa-sponsored-adr-nasdaq-abvx-stock-now-rated-moderate-buy-by-sell-side-analysts-2026-10-16/
Vilga Financial Planning LLC Acquires 22,000 Shares of Abivax SA Sponsored ADR $ABVX
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vilga-financial-planning-llc-acquires-22000-shares-of-abivax-sa-sponsored-adr-abvx-2026-10-09/
Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization
October 7, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/abivax-abvx-cleared-safety-overhang-and-phase-3-data-de-risk-path-to-commercialization-1850357/
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LP
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-676589-shares-in-abivax-sa-sponsored-adr-abvx-acquired-by-two-seas-capital-lp-2026-10-06/
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-abivax-nasdaq-abvx-stock-price-down-51-should-you-sell-2026-10-01/
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
September 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/abivax-to-present-data-on-obefazimod-at-united-european-gastroenterology-ueg-week-2026-1036587331
EQS-News: Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
September 30, 2026  |  sharewise.comS
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026
September 30, 2026  |  zonebourse.comZ
Abivax (NASDAQ:ABVX) Shares Climb 4.4% - Should You Buy?
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-abivax-nasdaq-abvx-shares-climb-44-should-you-buy-2026-09-28/
ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/abivax-soci-t-anonyme-enxtpa-190847577.html
ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/abivax-abvx-uses-more-cash-040326970.html
Abivax (NASDAQ:ABVX) Cut to "Sell" at Wall Street Zen
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-abivax-nasdaq-abvx-cut-to-sell-at-wall-street-zen-2026-09-26/
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and NewAmsterdam Pharma Company (NAMS)
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NAMS/pressreleases/4753959/analysts-offer-insights-on-healthcare-companies-abivax-sa-sponsored-adr-abvx-and-newamsterdam-pharma-company-nams/
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and Eli Lilly & Co (LLY)
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/4752241/analysts-offer-insights-on-healthcare-companies-abivax-sa-sponsored-adr-abvx-and-eli-lilly-co-lly/
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
September 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949076-abivax-priced-right-ahead-of-2-make-or-break-catalysts
Abivax (NASDAQ:ABVX) Shares Down 3.4% Following Weak Earnings
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-abivax-nasdaq-abvx-shares-down-34-following-weak-earnings-2026-09-22/
Abivax (NASDAQ:ABVX) Price Target Lowered to $151.00 at Truist Financial
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-abivax-nasdaq-abvx-price-target-lowered-to-15100-at-truist-financial-2026-09-22/
Abivax (NASDAQ:ABVX) Given New $118.00 Price Target at Wedbush
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-abivax-nasdaq-abvx-given-new-11800-price-target-at-wedbush-2026-09-22/
Barclays Reaffirms Overweight Rating for Abivax (NASDAQ:ABVX)
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-barclays-reaffirms-overweight-rating-for-abivax-nasdaq-abvx-2026-09-22/
Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692839/abivax-h1-net-loss-widens-plans-obefazimod-nda-for-ulcerative-colitis-by-end-of-2026.aspx

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$283.07 -0.41 (-0.14%)
Closing price 10/15/2026 03:59 PM Eastern
Extended Trading
$285.68 +2.60 (+0.92%)
As of 05:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abivax stock logo

Abivax NASDAQ:ABVX

$92.38 +4.40 (+5.00%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$91.91 -0.47 (-0.51%)
As of 05:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas